Additionally, the in silico gene expression profiling of acute myeloid leukaemia cell samples from a database revealed that lower expression levels of TAS2R5, TAS2R9, TAS2R10 or TAS2R14 were linked with some clinical parameters, i.e., TP53 and TET2 mutations, as well as higher molecular and cytogenetic risks, indicating poor prognosis [19]. This evidence concerns the gene TAS2R10 and acute myeloid leukemia.